Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE reported.; Patient received the less than recommended dose for the 2nd dose (human user error-needle was not placed tightly on the GARDASIL 9 ) .; Patient received the less than recommended dose for the 2nd dose (human user error-needle was not placed tightly on the GARDASIL 9 ) .; Male patient received first dose of GARDASIL 9 at age 14 on 7/24/2024, 2nd dose was administered on 8/15/2025.; This spontaneous report was received from a Nurse Practitioner on 15-Aug-2025 and refers to a 15-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 24-Jul-2024 at age of 14-years old, the patient was vaccinated with a first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), 1 dosage form total (lot # and expiration date were not reported) for prophylaxis. On 15-Aug-2025, the patient received a second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), the less than recommended dose, 1 dosage form , (lot # and expiration date were not reported) (underdose, Inappropriate schedule of product administration) (human user error-needle was not placed tightly on the Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (Wrong technique in product usage process)for prophylaxis. No additional adverse event reported. Lot # will be requested and will be submitted if received.